proprietari
extract
found
effect
prevent
upper
respiratori
infect
uri
healthi
adult
institution
communitydwel
senior
multicent
random
doubleblind
placebocontrol
trial
carri
determin
effect
prevent
uri
influenzavaccin
communitydwel
adult
communitydwel
adult
random
receiv
placebo
mg
mg
treatmentd
month
primari
analysi
incid
laboratoryconfirmedclin
uri
lccu
includ
influenza
b
perform
receiv
least
one
dose
secondari
analysi
perform
studi
complet
includ
incid
sever
durat
uri
meet
jacksonbas
criteria
safeti
incid
lccu
itt
group
placebo
mg
mg
group
respect
p
jacksonconfirm
uri
significantli
lower
treat
group
p
supplement
reduc
sever
durat
jacksonconfirm
uri
result
indic
safe
use
similar
group
may
prevent
symptom
uri
larger
sampl
size
warrant
virus
import
caus
morbid
mortal
elderli
patient
respiratori
viral
infect
particularli
influenza
remain
signific
caus
death
communitydwel
older
adult
influenza
vaccin
may
limit
efficaci
popul
possibl
due
ageassoci
declin
humor
cellmedi
immun
respons
case
influenza
influenzavaccin
senior
repres
vaccin
failur
therapi
enhanc
antiinfluenza
respons
influenzavaccin
senior
would
therapeut
benefit
popul
coldfx
patent
polyfuranosylpyranosylsaccharidebas
extract
panax
quinquefoliu
known
immunomodulatori
properti
evid
numer
vitro
anim
studi
indic
act
tolllik
receptor
stimul
innat
acquir
immun
enhanc
immun
respons
viral
infect
exampl
studi
human
peripher
blood
mononuclear
cell
cultur
live
influenza
viru
found
enhanc
product
anoth
studi
increas
express
natur
killer
nk
cell
cultur
influenza
viru
jing
intern
report
daili
administr
week
mice
viralinduc
leukemia
found
increas
proport
macrophag
nk
cell
bone
marrow
spleen
treat
anim
clinic
efficaci
also
demonstr
prevent
treatment
viral
upper
respiratori
infect
uri
particular
influenza
healthi
adult
institution
communitydwel
senior
present
studi
largest
multicent
studi
date
examin
efficaci
daili
dose
prevent
uri
communitydwel
senior
receiv
currentseason
influenza
vaccin
also
studi
date
systemat
assess
full
panel
viral
caus
respiratori
infect
senior
take
prevent
first
studi
look
impact
dose
efficaci
hypothes
regular
supplement
influenza
season
would
maintain
immun
stimul
therefor
would
reduc
incid
sever
durat
viral
uri
otherwis
healthi
influenzavaccin
senior
also
hypothes
dose
respons
would
observ
result
improv
efficaci
mgd
observ
mgd
specif
object
studi
determin
doserel
prophylact
efficaci
communitydwel
influenzavaccin
senior
incid
laboratoryconfirmedclin
uri
evalu
effect
incid
frequenc
uri
meet
jacksonbas
criteria
determin
efficaci
supplement
sever
durat
uri
assess
safeti
toler
chronic
administr
two
dosag
older
adult
recruit
senior
done
dissemin
studi
detail
inform
session
distribut
studi
advertis
local
influenza
immun
clinic
commun
senior
center
group
interest
screen
inclusionexclus
criteria
studi
coordin
elig
particip
includ
season
vaccin
influenza
avail
followup
visit
also
will
abl
sign
written
inform
consent
subject
follow
medic
condit
exclud
hiv
infect
malign
unstabl
cardiovascular
diseas
renal
abnorm
pulmonari
diseas
acut
activ
chronic
liver
diseas
neurolog
psychiatr
diseas
activ
tuberculosi
multipl
sclerosi
bleed
disord
plan
surgeri
cours
trial
current
take
immunosuppress
therapi
oral
steroid
dose
equival
prednison
mgday
phenelzin
pentobarbit
haloperidol
warfarin
heparin
also
exclud
addit
histori
alcoholdrug
abus
known
allergi
ginseng
allow
particip
use
natur
health
product
particip
studi
also
allow
particip
log
daili
dose
record
concomit
medic
consum
studi
addit
record
advers
event
experienc
studi
uri
consid
experiment
endpoint
includ
advers
event
list
ae
classifi
infect
includ
bladder
infect
bone
infect
skin
infect
lower
respiratori
tract
infect
pneumonia
note
sinc
pain
pulmonari
ae
could
refer
nonurirel
event
eg
arthriti
pain
sinc
uri
definit
requir
multipl
symptom
certain
intens
durat
direct
correl
ae
categori
incid
jacksonconfirm
uri
subject
maintain
dose
even
uri
told
tri
avoid
addit
medic
uri
unless
prescrib
physician
initi
onemonth
suppli
medic
given
subject
addit
medic
distribut
month
particip
final
visit
schedul
month
schedul
visit
return
complet
studi
log
leftov
medic
addit
blood
pressur
measur
complet
visit
also
requir
immedi
call
studi
coordin
develop
symptom
respiratori
infect
nasopharyng
swab
obtain
studi
coordin
within
day
onset
uri
symptom
test
influenza
b
parainfluenza
respiratori
syncyti
viru
adenoviru
coronaviru
rhinoviru
specimen
process
central
viral
laboratori
use
standard
virolog
method
consist
viral
cultur
pcr
direct
fluoresc
antibodi
analysi
swab
particip
contact
weekli
studi
ensur
adher
studi
protocol
studi
agent
proprietari
product
afexa
life
scienc
inc
standard
use
patent
dual
fingerprint
techniquechembioprintto
ensur
chemic
pharmacolog
consist
studi
compar
effect
two
dosag
mgday
placebo
placebo
capsul
contain
microcrystallin
cellulos
mcc
indistinguish
appear
color
size
treatment
capsul
bottl
label
ident
patient
id
number
differenti
bottl
subject
consent
obtain
random
studi
coordin
use
onetoonetoon
alloc
placebo
two
arm
use
block
random
block
size
creat
ega
bioscienc
independ
compani
treatment
consist
take
capsul
studi
medic
twice
everi
day
month
follow
onset
influenza
season
time
dose
relat
dose
meal
specifi
blind
could
broken
case
seriou
advers
event
use
treatment
code
provid
ega
bioscienc
investig
individu
seal
opaqu
envelop
uri
subject
complet
daili
log
sever
urirel
symptom
scale
symptom
mild
symptomno
chang
daili
activ
moder
symptomsom
decreas
abil
carri
daili
activ
sever
symptomconfin
home
bed
follow
symptom
evalu
sore
throat
runni
nose
nasal
congest
cough
myalgia
sneez
ear
ach
headach
fever
chill
fatigu
subject
complet
daili
log
approxim
time
day
daili
symptom
score
day
score
exceed
report
sum
calcul
total
symptom
score
tss
primari
end
point
studi
incid
acut
respiratori
ill
refer
laboratoryconfirmedclin
uri
studi
period
laboratori
confirm
defin
posit
result
virus
test
swab
sampl
clinic
infect
defin
presenc
least
two
follow
symptom
cough
headach
sore
throat
fever
report
uri
also
evalu
use
valid
symptom
selfassess
tool
assess
tool
refer
jackson
criteria
subject
consid
jacksonconfirm
uri
tss
two
success
day
greater
equal
least
one
follow
symptom
present
sore
throat
runni
nose
nasal
congest
cough
adequaci
blind
assess
complet
studi
medic
percept
questionnair
subject
complet
last
visit
center
complianc
assess
count
capsul
return
verifi
check
subject
daili
log
sampl
size
calcul
assum
proport
subject
laboratoryconfirmedclin
uri
control
group
would
supplement
either
dose
would
reduc
incid
less
detect
absolut
reduct
power
signific
level
twosid
subject
per
group
requir
allow
multipl
comparison
loss
followup
total
subject
per
group
enrol
result
total
sampl
size
subject
analysi
perform
independ
statistician
blind
condit
random
subject
receiv
least
one
dose
studi
medic
includ
primari
efficaci
analysi
group
refer
intentiontotreat
itt
popul
data
also
analyz
subject
complet
studi
betweengroup
comparison
primari
end
point
made
use
logrank
statist
timetoinfect
approach
itt
group
use
chisquar
test
compar
proport
subject
complet
studi
includ
secondari
efficaci
variabl
includ
rate
jacksonconfirm
uri
sever
durat
uri
safeti
chronic
administr
itt
group
betweengroup
comparison
uri
made
use
logrank
statist
subject
complet
studi
rate
jacksonconfirm
uri
compar
use
chisquar
test
total
symptom
score
total
day
infect
three
group
compar
use
wilcoxon
twosampl
test
incid
advers
event
advers
event
categori
seriou
advers
event
compar
use
chisquar
test
compar
proport
betweengroup
comparison
measur
complianc
proport
patient
least
compliant
made
use
analysi
varianc
chisquar
test
respect
percentag
subject
treatment
group
thought
take
percentag
subject
perceiv
treatment
effect
compar
use
chisquar
test
compar
proport
sa
version
use
perform
statist
analysi
follow
screen
process
total
volunt
recruit
center
across
canada
figur
receiv
placebo
mgday
mgday
respect
thirti
five
subject
placebo
group
group
group
exclud
analysi
reason
exclus
describ
figur
total
subject
includ
statist
analysi
primari
efficaci
endpoint
placebo
group
group
group
total
subject
placebo
group
group
group
withdrew
studi
figur
thu
total
subject
placebo
group
group
group
respect
complet
studi
p
three
group
found
balanc
term
age
gender
smoke
statu
weight
height
bodi
mass
index
blood
pressur
tabl
complianc
found
similar
among
group
studi
complet
data
shown
howev
significantli
greater
group
placebo
group
itt
popul
p
tabl
primari
endpoint
studi
rate
labconfirmedclin
uri
rate
uri
itt
group
n
found
placebo
group
respect
p
tabl
subject
complet
studi
n
rate
laboratoryconfirmedclin
uri
found
placebo
group
respect
p
infect
rate
individu
virus
test
studi
found
similar
among
group
statist
signific
betweengroup
differ
seen
tabl
addit
incid
lccu
incid
clinic
defin
uri
examin
use
clinic
criteria
uri
jacksonbas
criteria
valid
improv
type
measur
clinic
relev
proport
subject
itt
group
n
jacksonconfirm
uri
placebo
group
group
group
p
tabl
previou
studi
demonstr
efficaci
appar
final
week
treatment
period
analysi
complet
includ
particip
complet
entir
cours
studi
among
subject
complet
studi
n
rate
jacksonconfirm
uri
found
placebo
group
group
group
p
dose
found
significantli
reduc
number
uri
p
mgday
p
mgday
subject
complet
studi
effect
treatment
number
durat
sever
influenza
research
treatment
uri
also
present
tabl
overal
betweengroup
comparison
reveal
treatment
signific
effect
number
sever
durat
labconfirm
clinic
uri
howev
number
jacksonconfirm
urissubject
found
significantli
reduc
take
p
addit
regular
dose
either
mgday
mgday
result
statist
signific
reduct
symptom
durat
total
day
uri
p
symptom
sever
tss
p
jacksonconfirm
uri
report
incid
advers
event
report
well
seriou
advers
event
present
tabl
percentag
subject
experienc
advers
event
differ
group
p
statist
comparison
also
made
categori
amonggroup
differ
except
cardiovascular
advers
event
found
significantli
lower
group
p
total
subject
experienc
seriou
advers
event
studi
placebo
group
myocardi
infarct
hypotens
angina
gastroenter
bowel
resect
polyp
remov
appendectomi
hernia
surgeri
ataxia
prostat
cancer
sever
pain
back
leg
group
atrial
fibril
chest
pain
fatal
heart
attack
gall
bladder
surgeri
append
fractur
arm
broken
sternum
bone
infect
prostat
cancer
asthmat
bronchiti
cerebrovascular
accid
faint
group
pulmonari
embol
cardiac
arrest
basal
cell
carcinoma
diarrhea
nausea
epistaxi
bruis
rib
chest
pain
bladder
infect
mass
prostat
p
sae
deem
possibl
relat
studi
medic
placebo
group
ataxia
gastroenter
group
asthmat
bronchiti
append
group
pulmonari
embol
cardiac
arrest
one
fatal
myocardi
infarct
group
also
report
deem
unlik
relat
studi
medic
treatment
code
broken
subject
one
placebo
group
one
group
subject
percept
studi
medic
also
evalu
comparison
treatment
group
reveal
differ
percentag
believ
take
p
perceiv
treatment
effect
p
data
shown
proport
subject
take
concomit
medic
differ
group
found
placebo
group
respect
data
shown
coldfx
proprietari
product
afexa
life
scienc
inc
found
effect
prevent
uri
includ
influenza
varieti
popul
includ
healthi
adult
institution
senior
communitydwel
adult
present
studi
design
evalu
possibl
doserel
effect
administ
influenzavaccin
otherwis
healthi
communitydwel
senior
year
particular
subject
season
immun
influenza
recruit
determin
supplement
would
provid
addit
prophylaxi
provid
vaccin
alway
protect
popul
result
indic
regular
supplement
winter
month
effect
reduc
number
jacksonconfirm
respiratori
infect
healthi
senior
treatment
howev
found
signific
effect
incid
laboratoryconfirm
clinic
uri
result
somewhat
differ
earlier
studi
regular
dose
found
effect
reduc
incid
acut
respiratori
ill
due
influenza
rsv
influenzavaccin
institution
senior
discrep
result
could
explain
present
studi
milder
natur
influenza
outbreak
lower
rate
posit
respiratori
viral
infect
among
particip
may
result
insuffici
power
manifest
treatment
effect
delay
collect
transport
swab
sampl
may
also
contribut
unexpectedli
low
rate
laboratoryconfirm
infect
result
lack
efficaci
meet
primari
end
point
design
clinic
trial
base
design
use
studi
product
direct
impact
viru
period
time
sinc
clinic
trial
design
increas
knowledg
mechan
action
led
understand
belong
new
therapeut
class
polymolecular
botan
drug
impact
host
immun
system
rather
viru
new
inform
indic
endpoint
incid
lccu
design
studi
efficaci
antivir
medic
relev
studi
clinic
endpoint
despit
insuffici
number
laboratoryconfirm
infect
valid
primari
outcom
measur
supplement
found
affect
secondari
outcom
measur
significantli
among
subject
complet
studi
popul
subject
complet
studi
use
analysi
evid
previou
trial
threshold
time
requir
treatment
effect
size
measur
particularli
effect
reduc
number
uri
meet
jacksonbas
criteria
criteria
base
upon
subject
percept
sever
symptom
use
clinic
criteria
uri
valid
improv
measur
clinic
relev
supplement
mgday
mgday
found
reduc
rel
risk
jacksonconfirm
uri
respect
tabl
number
need
treat
dose
mgday
mgday
found
respect
tss
durat
uri
also
found
reduc
result
agreement
earlier
studi
healthi
adult
regular
dose
influenza
season
found
effect
reduc
number
sever
durat
jacksonconfirm
uri
although
underli
mechan
effect
determin
present
studi
evid
earlier
studi
indic
immun
modul
properti
may
involv
known
act
tolllik
receptor
stimul
innat
immun
respons
therefor
possibl
enhanc
inflammatori
respons
innat
cell
respiratori
virus
may
reduc
viral
load
henc
prevent
shorten
durat
respiratori
symptom
observ
reduct
cardiovascular
advers
event
particip
take
unexpect
warrant
evalu
present
studi
also
compar
efficaci
two
differ
dose
incid
durat
sever
uri
high
risk
popul
despit
fact
dose
mgday
produc
greater
reduct
number
sever
durat
jacksonconfirm
uri
dose
mgday
differ
group
signific
dose
safe
well
toler
taken
regularli
season
prophylaxi
observ
differ
incid
advers
event
subject
treatment
placebo
arm
treatmentrel
seriou
advers
event
observ
conclus
although
signific
betweengroup
differ
seen
lccu
data
indic
dose
mgday
mgday
safe
well
toler
result
reduct
number
sever
durat
jacksonconfirm
uri
taken
season
prophylaxi
healthi
communitydwel
older
adult
studi
larger
sampl
size
warrant
determin
possibl
doserel
effect
